News

Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.

Olaparib is now FDA approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer and who have already undergone chemotherapy before or after surgery.

New data support the use of ribociclib plus letrozole in the treatment of patients with postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Lindsay Kroener, MD, offers an overview of current fertility preservation options for patients about to undergo cancer therapy.

Investigators are looking to evaluate whether immunotherapy in the frontline setting, with or without chemotherapy, might improve prognoses for advanced esophageal squamous cell carcinoma.

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.

Patients with HER2-negative, locally advanced or metastatic breast cancer have experienced improved survival rates both in real-world data and the phase 3 EMBRACA trial.

Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.

Frontline treatment with poziotinib yielded promising overall response rates in patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.

The general population experienced nearly double the amount of anxiety and depression that patients with non–small cell lung cancer reported during the COVID-19 pandemic.

The FDA has granted a priority review designation of ivosidenib plus azacitidine on the indication of previously untreated IDH1-mutated acute myeloid leukemia.

Ahead of his presentation at the 39th Annual Miami Breast Cancer Conference, Charles L. Loprinzi, MD, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer.

At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.

Nivolumab combined with chemotherapy is now approved in the resectable non–small cell lung cancer setting.

Emerging from the HazeTM, a cognitive rehabilitation program, is a combination of didactic and experiential content focused on brain health to provide participants with a toolbox of strategies to help them cope with cancer treatment-related cognitive impairment.

Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.

A proactive, multidisciplinary approach is the best way to address belantamab mafodotin—related keratopathy in patients with multiple myeloma.

A new symptom-management guide designed by oncology nurses helps women with ovarian cancer feel more in control of their symptoms.

A comprehensive literature review underscores research gaps into optimal exercise regimens for childhood cancer survivors.

An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.

In this episode of “The Vitals,” Matt Iwaniec, PsyD, discusses the value of integrated behavioral health programs in cancer care.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

The FDA has initiated a priority review for neoadjuvant nivolumab plus chemotherapy to treat patients with resectable non–small cell lung cancer.

The FDA has approved pacritinib for patients with cytopenic myelofibrosis and severe thrombocytopenia.

Newly FDA-approved ciltacabtagene autoleucel was found to induce an objective response rate of 98% in patients with relapsed/refractory multiple myeloma.

Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Selinexor, an oral selective inhibitor of nuclear export, demonstrated promising efficacy in increasing progression-free survival among women with advanced endometrial cancer.

Adjuvant mitotane did not yield a significantly reduced risk of recurrence among patients with adrenocortical carcinoma.

Janice Post-White, PhD, RN, FAAN, an oncology nurse and caregiver, discusses how she handled the guilt she felt following her son’s leukemia diagnosis.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.